ALCAM (CD166) Expression as Novel Prognostic Biomarker for Pancreatic Neuroendocrine Tumor Patients

2011 ◽  
Vol 170 (2) ◽  
pp. 226-232 ◽  
Author(s):  
Michael Tachezy ◽  
Hilke Zander ◽  
Andreas H. Marx ◽  
Florian Gebauer ◽  
Tamina Rawnaq ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Prognostic Biomarker ◽  
Pancreatic Neuroendocrine Tumor ◽  
Tumor Patients

ALCAM (CD166) Expression As Novel Prognostic Biomarker For Pancreatic Neuroendocrine Tumor Patients

2011 ◽  
Vol 165 (2) ◽  
pp. 223-224
Author(s):  
M. Tachezy ◽  
H. Zander ◽  
S. Minner ◽  
F. Gebauer ◽  
T. Rawnaq ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Prognostic Biomarker ◽  
Pancreatic Neuroendocrine Tumor ◽  
Tumor Patients

Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors

2008 ◽  
Vol 26 (20) ◽  
pp. 3403-3410 ◽  
Author(s):  
Matthew H. Kulke ◽  
Heinz-Josef Lenz ◽  
Neal J. Meropol ◽  
James Posey ◽  
David P. Ryan ◽  
...  
Keyword(s):  
Growth Factor ◽  
Tyrosine Kinase ◽  
Neuroendocrine Tumor ◽  
Neuroendocrine Tumors ◽  
Objective Response ◽  
Pancreatic Neuroendocrine Tumor ◽  
Endocrine Tumor ◽  
Pancreatic Endocrine Tumor ◽  
Tumor Patients ◽  
Patient Reported

Purpose Standard cytotoxic chemotherapy has limited efficacy in metastatic neuroendocrine tumor patients. Neuroendocrine tumors express vascular endothelial growth factor (VEGF) and its receptor (VEGFR). Sunitinib malate, an oral tyrosine kinase inhibitor, has activity against VEGFRs as well as platelet-derived growth factor receptors, stem-cell factor receptor, glial cell line–derived neurotrophic factor, and FMS-like tyrosine kinase-3. We evaluated the efficacy of sunitinib in a two-cohort, phase II study of advanced carcinoid and pancreatic neuroendocrine tumor patients. Patients and Methods Patients were treated with repeated 6-week cycles of oral sunitinib (50 mg/d for 4 weeks, followed by 2 weeks off treatment). Patients were observed for response, survival, and adverse events. Patient-reported outcomes were assessed. Results Among 109 enrolled patients, 107 received sunitinib (carcinoid, n = 41; pancreatic endocrine tumor, n = 66). Overall objective response rate (ORR) in pancreatic endocrine tumor patients was 16.7% (11 of 66 patients), and 68% (45 of 66 patients) had stable disease (SD). Among carcinoid patients, ORR was 2.4% (one of 41 patients), and 83% (34 of 41 patients) had SD. Median time to tumor progression was 7.7 months in pancreatic neuroendocrine tumor patients and 10.2 months in carcinoid patients. One-year survival rate was 81.1% in pancreatic neuroendocrine tumor patients and 83.4% in carcinoid patients. No significant differences from baseline in patient-reported quality of life or fatigue were observed during treatment. Conclusion Sunitinib has antitumor activity in pancreatic neuroendocrine tumors; its activity against carcinoid tumors could not be definitively determined in this nonrandomized study. Randomized trials of sunitinib in patients with neuroendocrine tumors are warranted.

scholarly journals Impact of perioperative blood transfusion on survival in pancreatic neuroendocrine tumor patients: analysis from the US Neuroendocrine Study Group

HPB ◽  
2020 ◽  
Vol 22 (7) ◽  
pp. 1042-1050
Author(s):  
Paula Marincola Smith ◽  
Jordan Baechle ◽  
Carmen C. Solórzano ◽  
Marcus Tan ◽  
Alexandra G. Lopez-Aguiar ◽  
...  
Keyword(s):  
Blood Transfusion ◽  
Neuroendocrine Tumor ◽  
Pancreatic Neuroendocrine Tumor ◽  
Study Group ◽  
Tumor Patients ◽  
The Us ◽  
Perioperative Blood Transfusion

Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes

2016 ◽  
Vol 12 (10) ◽  
pp. 1251-1260 ◽  
Author(s):  
Sara Pusceddu ◽  
Roberto Buzzoni ◽  
Claudio Vernieri ◽  
Laura Concas ◽  
Sara Marceglia ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Pancreatic Neuroendocrine Tumor ◽  
Tumor Patients ◽  
Patients With Diabetes

scholarly journals Insulin-dependence predicts disease-specific survival in pancreatic neuroendocrine tumor patients

HPB ◽  
2019 ◽  
Vol 21 ◽  
pp. S57
Author(s):  
J.J. Baechle ◽  
P.M. Smith ◽  
C.E. Bailey ◽  
A.G. Lopez-Aguiar ◽  
M. Dillhoff ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Pancreatic Neuroendocrine Tumor ◽  
Disease Specific Survival ◽  
Tumor Patients ◽  
Insulin Dependence ◽  
Disease Specific
Sign in / Sign up

Export Citation Format

Share Document